We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
- Recent LXEO Stock Price: $11.94
- Yearly Gain for LXEO stock: 9.45%
- Market Cap for LXEO stock: ―
- P/E Ratio for LXEO stock:
Will LXEO's stock price go up? Is there an accurate LXEO stock forecast available?
TipRanks.com reports that Lexeo Therapeutics, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $20.80. The target pricing ranges from a high LXEO forecast of $23 down to a low forecast of $19. Lexeo Therapeutics, Inc. (LXEO)’s last closing stock price was $11.94 which would put the average price target at 74.20% upside.
In addition, TradingView issued a rating for LXEO stock over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on LXEO stock.
Other analysts covering LXEO include:
- Paul Matteis of Stifel Nicolaus issued a Buy rating with the price target of $20 on 21 hours ago
- Mani Foroohar of Leerink Partners issued a Buy rating with the price target of $19 on 21 hours ago
- Tessa Romero of J.P. Morgan issued a Buy rating with the price target of $20 on 21 hours ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $22 on 21 hours ago
If you are wondering if LXEO is a good stock to buy, here are 3rd party ratings for LXEO stock:
- TipRanks.com: Strong Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: n/a
What is the sentiment on the street regarding Lexeo Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for LXEO stock: Neutral
- Blogger Consensus for LXEO stock: ―
- Media Buzz for LXEO stock: Medium
- Insider Signal for LXEO stock: Very Positive
- Investor Sentiment for LXEO stock: ―
- Hedge Fund signal for LXEO stock: No Signal
The stock market is extremely volatile, and you need to do your own research on LXEO stock including scouring the social networks like LXEO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LXEO stock chart >>
Summary: Veeva Systems Inc. offers cloud-based software applications and data solutions for the life sciences industry. The company's product portfolio includes Veeva CRM (customer relationship management), Veeva Vault (content and information management), Veeva Network (customer master and product data management) and Veeva data services (Veeva OpenData and Veeva KOL data).
- Recent VEEV Stock Price: $174.76
- Yearly Gain for VEEV stock: -4.99%
- Market Cap for VEEV stock: $28.37B
- P/E Ratio for VEEV stock: 52.141
Will VEEV's stock price go up? Is there an accurate VEEV stock forecast available?
TipRanks.com reports that Veeva Systems currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $189.00. The target pricing ranges from a high VEEV forecast of $220 down to a low forecast of $160. Veeva Systems (VEEV)’s last closing stock price was $174.76 which would put the average price target at 23.31% upside.
In addition, TradingView issued a rating for VEEV stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VEEV stock.
Other analysts covering VEEV include:
- Jailendra Singh of Truist Financial issued a Hold rating with the price target of $187 on 2 weeks ago
- Craig Hettenbach of Morgan Stanley issued a Sell rating with the price target of $160 on 2 weeks ago
If you are wondering if VEEV is a good stock to buy, here are 3rd party ratings for VEEV stock:
- TipRanks.com: Moderate Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 12% (31 out of 251)
What is the sentiment on the street regarding Veeva Systems? (Current ratings compiled by TipRanks.com)
- News Sentiment for VEEV stock: Very Bullish
- Blogger Consensus for VEEV stock: Bullish
- Media Buzz for VEEV stock: Low
- Insider Signal for VEEV stock: ―
- Investor Sentiment for VEEV stock: Negative
- Hedge Fund signal for VEEV stock: Negative
The stock market is extremely volatile, and you need to do your own research on VEEV stock including scouring the social networks like VEEV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VEEV stock chart >>
Summary: Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.
- Recent SLRN Stock Price: $5.88
- Yearly Gain for SLRN stock: -62.98%
- Market Cap for SLRN stock: $850.75M
- P/E Ratio for SLRN stock:
Will SLRN's stock price go up? Is there an accurate SLRN stock forecast available?
TipRanks.com reports that ACELYRIN, INC. currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $30.75. The target pricing ranges from a high SLRN forecast of $68 down to a low forecast of $12. ACELYRIN, INC. (SLRN)’s last closing stock price was $5.88 which would put the average price target at 422.96% upside.
In addition, TradingView issued a rating for SLRN stock over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SLRN stock.
Other analysts covering SLRN include:
- Vikram Purohit of Morgan Stanley issued a Hold rating with the price target of $13 on 21 hours ago
- Akash Tewari of Jefferies issued a Buy rating with the price target of $12 on 1 day ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $68 on 1 month ago
If you are wondering if SLRN is a good stock to buy, here are 3rd party ratings for SLRN stock:
- TipRanks.com: Strong Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Hold, Top 19% (47 out of 251)
What is the sentiment on the street regarding ACELYRIN, INC.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SLRN stock: Very Bullish
- Blogger Consensus for SLRN stock: Bullish
- Media Buzz for SLRN stock: Low
- Insider Signal for SLRN stock: ―
- Investor Sentiment for SLRN stock: Very Negative
- Hedge Fund signal for SLRN stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on SLRN stock including scouring the social networks like SLRN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SLRN stock chart >>
Summary: Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
- Recent ROIV Stock Price: $9.09
- Yearly Gain for ROIV stock: 80.55%
- Market Cap for ROIV stock: $7.34B
- P/E Ratio for ROIV stock: -6.903
Will ROIV's stock price go up? Is there an accurate ROIV stock forecast available?
TipRanks.com reports that Roivant Sciences currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.40. The target pricing ranges from a high ROIV forecast of $23 down to a low forecast of $11. Roivant Sciences (ROIV)’s last closing stock price was $9.09 which would put the average price target at 77.45% upside.
In addition, TradingView issued a rating for ROIV stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ROIV stock.
Other analysts covering ROIV include:
- Corinne Jenkins of Goldman Sachs issued a Buy rating with the price target of $14 on 21 hours ago
- Chi Meng Fong of Bank of America Securities issued a Hold rating with the price target of $11 on 1 day ago
- Dennis Ding of Jefferies issued a Buy rating with the price target of $16 on 1 week ago
- Robyn Karnauskas of Truist Financial issued a Buy rating with the price target of $23 on 2 weeks ago
If you are wondering if ROIV is a good stock to buy, here are 3rd party ratings for ROIV stock:
- TipRanks.com: Strong Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 19% (47 out of 251)
What is the sentiment on the street regarding Roivant Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for ROIV stock: Neutral
- Blogger Consensus for ROIV stock: Bullish
- Media Buzz for ROIV stock: Very Low
- Insider Signal for ROIV stock: Very Negative
- Investor Sentiment for ROIV stock: Very Negative
- Hedge Fund signal for ROIV stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ROIV stock including scouring the social networks like ROIV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ROIV stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
